PERSPECTIVE ARTICLE | VOLUME 4, ISSUE 1 | OPEN ACCESS DOI: 10.23937/2469-5807/1510069

C3orf21 and Notch Signaling in Cancer:A Potential Biomarker

Yongjun Zhang*, Dehou Deng and Wenlong Bao

Department of Integration of Traditional Chinese and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, China

*Corresponding author: Yongjun Zhang, Department of Integration of Traditional Chinese and Western Medicine, Zhejiang Cancer Hospital, 1# Banshandong Road, Hangzhou 310022, China.

Published: June 11, 2018

Citation: Zhang Y, Deng D, Bao W (2018) C3orf21 and Notch Signaling in Cancer: A Potential Biomarker. Int J Pathol Clin Res 4:069.

Copyright: © 2018 Zhang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


C3orf21 (chromosome 3 open reading frame 21), also known as xyloside xylosyltransferase 1 (XXYLT1), is located on chromosome 3q29. C3orf21 belongs to the glycosyltransferase 8 family, furthermore, it is a retaining glycosyltransferase. In the extracellular domain of target proteins, XXYLT1 catalyzes addition of the second sylose, and then elongates the O-linked xylose-glucose disaccharide attached to EGF-like repeats. XXYLT1 negatively regulates Notch signaling, and aberrations in the Notch signaling pathway were associated with a few types of cancers. So, C3orf21 must be associated with cancer development. Our previous research has found that the C3orf21 polymorphisms were associated with lung cancer risk, and the ablation of C3orf21 gene (XXYLT1) promoted lung cancer MSTO-211H cell proliferation, inhibited apoptosis and accelerated cell migration. Understanding the role of C3orf21 in the cancer development may provide insights into the potential of C3orf21 as a cancer biomarker. Here, we reviewed several representative studies for understanding the C3orf21 and Notch signaling in cancer.


Biomarker, Cancer, Chromosome 3 open reading frame 21, Notch pathway, Xyloside xylosyltransferase 1


The number of cancer survivors continues to increase because of the advancements in both early detection and treatment, especially in the target therapy. Thus, further understanding of the molecular basis of cancer may lead to the identification of new molecular targets. Notch signaling pathway is one of the several other signaling pathways that have been shown to play an essential role in the development of all metazoans, and defects in the Notch pathway lead to a variety of cancers [1-4]. Notch signaling activation is modulated by the differential O-linked glycosylation of its extracellular domain (NECD) [5]. Xylose is transferred to the O-glucosylated mammalian Notch epidermal growth factor (EGF) repeats [6] and an xyloside xylosyltransferase 1 (XXYLT1) enzyme to further elongate the Xyl-Glc-O-Ser disaccharide on Notch EGF repeats [7]. XXYLT1 has conformed in the negative regulation of Notch signaling [8]. C3orf21 (chromosome 3 open reading frame 21) gene is also known as chromosome 3 open reading frame 21 and is encoded by UDP-xylose: α-xylosideα1, 3-xylosyltransferase (XXYLT1). Previous research studies also reported that C3orf21 rs2131877 polymorphism (C/C + C/T > T/T) was nominally associated with a reduced risk of lung adenocarcinoma (OR = 0.619, 95% CI = 0.390-0.976) [9]. Its ablation was significantly associated with lung adenocarcinomas with a higher degree of malignance [10]. C3orf21 may act as a susceptible marker for cancer therapy. So, our review mainly focused on understanding the role of C3orf21 in cancer development.

Structure of C3orf21

XXYLT1 is a type II membrane protein located in the endoplasmic reticulum (ER) with its catalytic domain protruding into the lumen [11]. XXYLT1 belongs to glycosyltransferase family 8 (GT8) [12], and is a retaining GT, i.e. the α-linked xylose in the donor UDP-xylose retains its stereochemistry after being transferred to the acceptor xylose [7]. XXYLT1 was first identified using glucoside xylosyltransferase 1 (GXYLT1) in a position-specific iterated-Blast and possessed an N-terminal signal sequence or membrane anchor and two conserved DXD motifs (Figure 1) [11]. Following research studies found that XXYLT1 have a GT-A fold with glycosyltransferase signature DXD motif (residues 225-227) [13]. Yu H, et al. found that the binary structure of XXYLT1 with acceptor Xyl-Glc-EGF modifies the newly synthesized Notch receptor with multiple tandem EGF repeats. When the crystal structure of the binary complex XXYLT1: Xyl-Glc-EGF was oriented like apo-XXYLT1 (as in Figure 2a), the acceptor substrate Xyl-Glc-EGF indeed was bound to the side of the enzyme (Figure 2b). Superimposition of the human Notch1 EGF11-13 crystal structure on the XXYLT1-bound hFA9 EGF was oriented to the EGF11-13 N-terminus away from and the C-terminus toward the membrane [14]. The full-length XXYLT1 formed an SDS-resistant dimer via the AXXXA dimerization motif in the transmembrane helix [7].

Figure 1: Sequence alignment of Notch xylosyltransferases and overview of enzymes involved in Notch glycosylation. (A) Amino acid sequence alignment of XXYLT1 with GXYLT1 and GXYLT2; (B) Overview of enzymes involved in O-fucosylation and O-glucosylation of specific consensus sequences on EGF repeats [7]. View Figure 1

Figure 2: The mouse XXYLT1 is a dimer and has a GT-A fold with its site facing sideways to facilitate lateral modification of Notch. (a) The overall structure of type II membrane protein XXYlT1, with its truncated n-terminal transmembrane domain shown as a cylinder. The noncrystallographic two-fold axis is oriented upward and perpendicular to the sketched ER membrane in gray. The type I membrane protein notch receptor is sketched with its 36 EGF repeats as spheres. ICD, intracellular domain; H7, helix 7; H8, helix 8; H9, helix 9; Xyl-Glc, xylose-glucose disaccharide; (b) Left, overall structure of XXYlT1 in complex with hFA9 Xyl-Glc-eGF. right, superposition of the crystal structure of human noTCH1 eGF11–13 (PDb 2vJ3) with the acceptor EGF, showing that the enzyme interacts laterally with the protein substrates. XXYlT1 is in green and is in the same orientation as the green apo-XXYlT1 structure in a. Xyl-Glc-eGF is in magenta with a semitransparent surface view, and the covalently linked disaccharide is in spheres. The human noTCH1 eGF11-13 is shown in orange [14]. View Figure 2

XXYLT1 Activity and Function

The XXYLT1 played an important role in the trisaccharide synthesis, which catalyzes the transfer of xylose to Xylα1-3Glc, and form D-Xylpα1-3-D-Xylpαl- 3-D-Glc, X2G. XXYLT1 elongates the O-linked xylose-glucose disaccharide attached to the EGF-like repeats in the extracellular domain of target proteins by catalyzing the addition of the second xylose [7,15,16]. XXYLT1 participated in the biosynthesis of Glc-O-type sugar chains and encodes xylosyltransferase activity [17]. XXYLT1 was active only when linked with an acceptor containing Xylα1, 3Glcβ1, while no activity was observed when linked with xylose linked to pNP or with Xyl-O-EGF16 [18]. Furthermore, XXYLT1 activity required divalent cation participation, and showed its highest activity with 20 mM Mn2+ at pH 7.2. It can also utilize Mg2+, suggesting that this might be the physiological cofactor [15]. After XXYLT1 activities, it transfers the second xylose to O-glucosylated EGF repeats of Notch [7]. XXYLT1 was involved in the organogenesis. The rearrangement of 3q29 microdeletion/microduplication syndrome region including XXYLT1 was associated to Oculo auriculo vertebral specturm [19]. XXYLT1 microdeletion also was associated with Chiari malformation type II [20]. In addition, the XXYLT1 rs9825174 polymorphism was associated with associated with osteoporosis and obesity [21], and C3orf21 rs2720932 was associated with systemic lupus erythematosus (SLE) in the Korean population [22].

XXYLT1 and Notch signal and Cancer

The Notch signaling pathway is a short-range communication transducer that is involved in regulating many cellular processes (proliferation, stem cell and stem cell niche maintenance, cell fate specification, differentiation, and cell death) during development and renewal of adult tissues. The human Notch family includes four cell-bound notch receptors, namely Notch 1-4, and five Notch ligands, Jagged 1 (JAG1), JAG2, Delta-like 1 (DLL1), DLL3 and DLL4 [23,24]. There are 36 tandem EGF-like repeats in the Notch extracellular domain [25], they were modified by O-linked fucose, glucose, or N-acetylglucosamine (GlcNAc) [26]. Notch activation is modulated by the differential O-linked glycosylation of its extracellular domain (NECD) [20], whereby O-linked glucose is added to a subset of EGF repeats in the NECD domain by Protein O-glucosyltransferase 1 (POGLUT1) [5,27,28]. This can be subsequently extended to xylose α1-3 glucose trisaccharide by the sequential action of Glucoside α1-3 xylosyl transferase (GXYLT1/2) [17] and xyloside α1-3 xylosyl transferase (XXYLT1) [29]. GXYLT1 and GXYLT2 (glucoside-xylosyltransferase 1/2) transfer the first 1,3-linked xylose to O-glucosylated mammalian Notch EGF repeats [29], while XXYLT1 can transfer the second xylose to o-glucosylated EGF repeats of Notch [7].

Notch signaling is a juxtacrine cell-cell communication pathway with broad roles in animal development and adult tissue homeostasis [19,30]. Both gain- and loss-of-function mutations in Notch pathway components cause human disease [31-33]. Now, the Notch signaling pathway has been an attractive target in cancer research. The study found that the oncogenic effects of Notch signaling are dependent on the type of cancer: In most cases, Notch aberrations were associated with a few types of cancers [2-4]. However, in some cases such as squamous carcinomas derived from the epidermis, lung, and head and neck, and acute myeloid leukemia, inactivation of Notch signaling is oncogenic [1]. The XXYLT1 negatively regulates Notch, and reduced activity of XXYLT1 would lead to enhanced Notch signaling [8]. These results suggested that XXYLT1 gene is associated with cancer and has been conformed in larger research studies: XXYLT1 gene amplification, mutation, deletion and multiple alterations were found in several cancer types. In cancers including breast, ovarian, esophagus, head & neck, cervical, uterine, especially in lung squamous cell carcinoma, the XXYLT1 has higher amplification incidence. Notably, the activity-reducing mutations occurred in cancers with much lower incidence of XXYLT1 amplification (Figure 3), in the same time, XXYLT1 gene have 22 cancer-associated missense mutations: In human lung adenocarcinoma, the XXYLT1 mutation was A (Alanine)→E (Glutamic) (Table 1) [14]. Chromosomal imbalance at 3q29 was found in various types of cancer, including Non-small cell lung cancer (NSCLC), prostate cancer and head and neck squamous cell carcinoma [34,35]. Our previous study has demonstrated that C3orf21 polymorphism was associated with reduced risk of never smoker adenocarcinoma [9]. In Korean population, genome-wide scan found that polymorphisms at 3q29 were significantly associated with lung cancer risk, particularly with an increased risk of NSCLC. Also, C3orf21 rs2131877 was considered as the most significant biomarker of lung cancer susceptibility [36]. Our recent work also indicated that the values of NSE (Neuron Specific Enolase) tumor marker were significantly higher in patients with rs2131877 T/C + C/C genotype. In vitro study of C3orf21 mRNA expression was associated with lung cancer risk and its ablation promoted lung cancer cell proliferation, inhibited apoptosis and accelerated cell migration [10]. These studies demonstrated that C3orf21 may be a potential anticancer treatment target.

Figure 3: The abnormal expression of human XXYLT1 in difference cancers. Gene alteration data were obtained from cancer genomics site: cBioPortal [14]. View Figure 3

Table 1: Compilation of XXYLT1 mutations identified in some cancers. View Table 1

Issues and Perspectives

From the aforementioned findings, we understood that C3orf21 is one of the members of the three genes that belong to the glycosyltransferase 8 family. These were formerly named as GLT8D3, GLT8D4, and C3ORF21, but were now named as GXYLT1, GXYLT2, and XXYLT1 according to their function. C3orf21 encodes xylosyltransferases that extends O-glucose on EGF-like repeats of Notch to form the trisaccharide, Xyl-Xyl-Glc-Ser [7,29]. But XXYLT1 negatively mediated Notch signaling because of its reduced activity, which would lead to enhanced Notch signaling [14]. This in turn hinders the normal cell differentiation, resulting in epithelial cell polarity disorder and also drives normal cell to tumor cell when mature NOTCH signaling was excessively activated [37]. This suggested that C3orf21 played a significant role in tumorigenesis. In our research, we found that ablation of C3orf21 gene (XXYLT1) promoted lung cancer, MSTO-211H cell proliferation, inhibited apoptosis and accelerated cell migration. At the same time, C3orf21 overexpression showed no significant alterations in cell proliferation or apoptosis [10]. Similar phenomenon has been observed in other studies. Notch 1 protein suppressed tumor proliferation under normoxic conditions in lung cancer; however, it exhibited the opposing role of tumor promotion under hypoxic conditions [38]. Furthermore, the role of Notch 1 played different roles in different stages of tumor development. For instance, it promoted tumor development in early-stage of cervical cancer and suppressed tumor development in late-stage cervical cancer [39-41]. Whether the carcinogenesis of C3orf21 overexpression was dependent on specific tissue context, microenvironment, and crosstalk with other signaling pathways needs further elucidation. Presently, some studies regarding the role of C3orf21 in cancer development have shed greater insights in the research of C3orf21 as a biomarker of cancer [9,10,14,36]. To date, there are a few studies about C3orf21 gene, while future studies should focus on the role of C3orf21 in carcinogenesis may provide novel and in-depth understanding of the C3orf21 physiology.


This study was supported by grants from Zhejiang Provincial Science Department Public Technology Application Research Fund (#2016C33056) and Zhejiang Provincial Medical and Health Scientific and Technical Fund (#2017171306).

Disclosure of Conflict of Interest



  1. Ntziachristos P, Lim JS, Sage J, Aifantis I (2014) From fly wings to targeted cancer therapies: A centennial for notch signaling. Cancer Cell 25: 318-334.

  2. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, et al. (2011) A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473: 230-233.

  3. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, et al. (2001) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 108: 17761-17766.

  4. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.

  5. Takeuchi H, Haltiwanger RS (2014) Significance of glycosylation in Notch signaling. Biochem Biophys Res Commun 453: 235-242.

  6. Cantarel BL, Coutinho PM, Rancurel C, Bernard T, Lombard V, et al. (2009) The Carbohydrate-Active EnZymes database (CAZy): An expert resource for glycogenomics. Nucleic Acids Res 37: 233-238.

  7. Sethi MK, Buettner FF, Ashikov A, Krylov VB, Takeuchi H, et al. (2012) Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glucosylated epidermal growth factor repeats of notch. J Biol Chem 287: 2739-2748.

  8. Lee TV, Sethi MK, Leonardi J, Rana NA, Buettner FF, et al. (2013) Negative regulation of notch signaling by xylose. PLoS Genet 9: e1003547.

  9. Zhang Y, Gu C, Shi H, Zhang A, Kong X, et al. (2012) Association between C3orf21, TP63 polymorphisms and environment and NSCLC in never-smoking Chinese population. Gene 49: 93-97.

  10. Yang L, Wang Y, Fang M, Deng D, Zhang Y (2017) C3orf21 ablation promotes the proliferation of lung adenocarcinoma, and its mutation at the rs2131877 locus may serve as a susceptibility marker. Oncotarget 8: 33422-33431.

  11. Lombard V, Golaconda Ramulu H, Drula E, Coutinho PM, Henrissat B (2014) The carbohydrate-active enzymes database (CAZy) in 2013. Nucleic Acids Res 42: 490-495.

  12. Lairson LL, Henrissat B, Davies GJ, Withers SG (2008) Glycosyltransferases: structures, functions, and mechanisms. Annu Rev Biochem 77: 521-555.

  13. Wiggins CA, Munro S (1998) Activity of the yeast MNN1 alpha-1,3- mannosyltransferase requires a motif conserved in many other families of glycosyltransferases. Proc Natl Acad Sci USA 95: 7945-7950.

  14. Yu H, Takeuchi M, LeBarron J, Kantharia J, London E, et al. (2015) Notch-modifying xylosyltransferase structures support an SNi-like retaining mechanism. Nat Chem Biol 11: 847-854.

  15. Minamida S, Aoki K, Natsuka S, Omichi K, Fukase K, et al. (1996) Detection of UDP-D-Xylose: α-D-xyloside α1→3xylosyltransferase activity in human hepatoma cell line HepG2. J Biochem 120: 1002-1006.

  16. Takeuchi H, Kantharia J, Sethi MK, Bakker H, Haltiwanger RS (2012) Site-specific O-glucosylation of the epidermal growth factor-like (EGF) repeats of notch: efficiency of glycosylation is affected by proper folding and amino acid sequence of individual EGF repeats. J Biol Chem 287: 33934-33944.

  17. Sethi MK, Buettner FF, Ashikov A, Bakker H (2013) In vitro assays of orphan glycosyltransferases and their application to identify Notch xylosyltransferases. Methods Mol Biol 1022: 307-320.

  18. Takeuchi H, Fernández-Valdivia RC, Caswell DS, Nita-Lazar A, Rana NA, et al. (2011) Rumi functions as both a protein O-glucosyltransferase and a protein O-xylosyltransferase. Proc Natl Acad Sci USA 108: 16600-16605.

  19. Guida V, Sinibaldi L, Pagnoni M, Bernardini L, Loddo S, et al. (2015) A de novo proximal 3q29 chromosome microduplication in a patient with oculo auriculo vertebral spectrum. Am J Med Genet A 167A: 797-801.

  20. Guo S, Fan XF, Jin JY, Fan LL, Zeng L, et al. (2018) A novel proximal 3q29 chromosome microdeletion in a Chinese patient with Chiari malformation type II and Sprengel's deformity. Mol Cytogenet 11: 8.

  21. Hu Y, Tan LJ, Chen XD, Liu Z, Min SS, et al. (2018) Identification of novel potentially pleiotropic variants associated with osteoporosis and obesity using the cFDR method. J Clin Endocrinol Metab 103: 125-138.

  22. Lee HS, Kim T, Bang SY, Na YJ, Kim I, et al. (2014) Ethnic specificity of lupus-associated loci identified in a genome-wide association study in Korean women. Ann Rheum Dis 73: 1240-1245.

  23. Pancewicz J, Nicot C (2011) Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer 11: 502.

  24. Liu N, Zhang J, Ji C (2013) The emerging roles of Notch signaling in leukemia and stem cells. Biomark Res 1: 23.

  25. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway. Unfolding the activation mechanism. Cell 37: 216-233.

  26. Takeuchi H, Haltiwanger RS (2010) Role of glycosylation of Notch in development. Semin Cell Dev Biol 21: 638-645.

  27. Acar M, Jafar-Nejad H, Takeuchi H, Rajan A, Ibrani D, et al. (2008) Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is required for Notch signaling. Cell 132: 247-258.

  28. Fernandez-Valdivia R, Takeuchi H, Samarghandi A, Lopez M, Leonardi J, et al. (2011) Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi. Development 138: 1925-1934.

  29. Sethi MK, Buettner FF, Krylov VB, Takeuchi H, Nifantiev NE, et al. (2010) Identification of glycosyltransferase 8 family members as xylosyltransferases acting on O-glucosylated notch epidermal growth factor repeats. J Biol Chem 285: 1582-1586.

  30. Artavanis-Tsakonas S, Muskavitch MA (2010) Notch: the past, the present, and the future. Curr Top Dev Biol 92: 1-29.

  31. Penton AL, Leonard LD, Spinner NB (2012) Notch signaling in human development and disease. Semin Cell Dev Biol 23: 450-457.

  32. Louvi A, Artavanis-Tsakonas S (2012) Notch and disease: A growing field. Semin Cell Dev Biol 23: 473-480.

  33. South AP, Cho RJ, Aster JC (2012) The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 23: 458-464.

  34. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM (2009) Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 9: 237.

  35. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, et al. (2007) Integrativ analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 67: 8229-8239.

  36. Yoon KA, Park JH, Han J, Park S, Lee GK, et al. (2010) A genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population. Hum Mol Genet 19: 4948-4954.

  37. Xu K, Moghal N, Egan SE (2012) Notch signaling in lung development and disease. Adv Exp Med Biol 727: 89-98.

  38. Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, et al. (2007) Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 67: 7954-7959.

  39. Wang L, Qin HB, Xin X, Li J, Han H (2007) Overexpressed active Notch1 induces cell growth arrest of HeLa cervical carcinoma cells. Int J Gynecol Cancer 17: 1283-1292.

  40. Sun Y, Zhang R, Zhou S, Ji Y (2015) Overexpression of Notch1 is associated with the progression of cervical cancer. Oncol Lett 9: 2750-2756.

  41. Cong L, Zhang F, Shang H (2017) Notch1 targeted regulation of mir-224/LRIG2 signaling for the proliferation and apoptosis of cervical cancer cells. Oncol Lett 13: 2304-2308.